Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominika Wieczorek

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 25, 2010
PSS-SQL: protein secondary structure - structured query languageDariusz Mrozek, Dominika Wieczorek, Bozena Malysiak-Mrozek, et al.
International Journal of Cardiology|September 15, 2010
Effects of high dose aleglitazar on renal function in patients with type 2 diabetesMatthias Herz, Flavio Gaspari, Norberto Perico, et al.
BMC Nephrology|November 20, 2014
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized studyLuis Ruilope, Markolf Hanefeld, A Michael Lincoff, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|November 25, 2010
PSS-SQL: protein secondary structure - structured query languageDariusz Mrozek, Dominika Wieczorek, Bozena Malysiak-Mrozek, et al.
International Journal of Cardiology|September 15, 2010
Effects of high dose aleglitazar on renal function in patients with type 2 diabetesMatthias Herz, Flavio Gaspari, Norberto Perico, et al.
BMC Nephrology|November 20, 2014
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized studyLuis Ruilope, Markolf Hanefeld, A Michael Lincoff, et al.
Pageof 1